AU2022203135B2 — Topical cyclosporine-containing formulations and uses thereof
Assigned to Sun Pharmaceutical Industries Ltd · Expires 2025-09-11 · 1y expired
What this patent protects
#$%^&*AU2022203135B220250911.pdf##### ABSTRACT Provided herein are formulations for topical ophthalmic formulations containing 0.087-0.093 wt% of cyclosporine, and methods of making and using such formulations. In some aspects and embodiments the formulations may include a…
USPTO Abstract
#$%^&*AU2022203135B220250911.pdf##### ABSTRACT Provided herein are formulations for topical ophthalmic formulations containing 0.087-0.093 wt% of cyclosporine, and methods of making and using such formulations. In some aspects and embodiments the formulations may include a polyoxyl lipid or fatty acid, and/or a polyalkoxylated alcohol and may include nanomicelles. Also included herein are methods of treating or preventing diseases or conditions, such as ocular diseases or conditions. ABSTRACT 2022203135 11 May 2022 Provided herein are formulations for topical ophthalmic formulations containing 0.087-0.093 wt% of cyclosporine, and methods of making and using such formulations. In some aspects and embodiments the formulations may include a polyoxyl lipid or fatty acid, and/or a polyalkoxylated alcohol and may include nanomicelles. Also included herein are methods of treating or preventing diseases or conditions, such as ocular diseases or conditions.
Drugs covered by this patent
- Sandimmune (cyclosporine) · Novartis AG (originally Sandoz)
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.